Regeneration of a deactivated surface functionalised polyacrylonitrile supported Fenton catalyst for use in wastewater treatment.

Successful attempts to regenerate a used surface functionalised nanocoated polyacrylonitrile (PAN) catalyst are described here. During use in wastewater treatment, the novel Fenton catalyst (F1) is deactivated due to iron loss caused by acid hydrolysis. In this study the deactivated catalyst (D1) is subjected to reactions with 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), followed by reactions with either hydroxylamine to give sample T1 or hydroxylamine and hydrazine to give sample T2.

Real-time monitoring of the mechanism of ibuprofen-cationic dextran crystanule formation using crystallization process informatics system (CryPRINS).

One step aqueous melt-crystallization and in situ granulation was utilized to produce ibuprofen-cationic dextran [diethylaminoethyl dextran (Ddex)] conjugate crystanules without the use of surfactants or organic solvents. This study investigates the mechanism of in situ granulation-induced crystanule formation using ibuprofen (Ibu) and Ddex. Laboratory scale batch aqueous crystallization system containing in situ monitoring probes for particle vision measurement (PVM), UV-vis measurement and focused beam reflectance measurements (FBRM) was adapted using pre-defined formulation and process parameters.

On clinical trials with a high placebo response rate.

The basic problem that causes the frequent failure of a standard randomized parallel placebo-controlled clinical trial with a high placebo response rate is the underestimation of the treatment effect by the observed relative treatment difference. A two-period sequential parallel enrichment design has been proposed where the first period is a standard parallel design and at the end of the first period, the placebo non-responders are identified and re-randomized in the second period. Based on such a design, available methods have primarily focused on testing either the first period treatment null hypothesis or the global null hypothesis defined as the joint period 1 and period 2 treatment effect null hypothesis by a test statistic which is either derived from a combined statistic or defined directly as a weighted z-score where the weights are functions of some population and design parameters satisfying certain power optimality criterion.

Quantification of in situ granulation-induced changes in pre-compression, solubility, dose distribution and intrinsic in vitro release characteristics of ibuprofen-cationic dextran conjugate crystanules.

The direct effect of intermolecular association between ibuprofen and diethylaminoethyl dextran (Ddex) and the novel 'melt-in situ granulation-crystallization' technique on the solubility, dose distribution, in vitro dissolution kinetics and pre-compression characteristics of the ibuprofen-Ddex conjugate crystanules have been investigated using various mathematical equations and statistical moments. The research intention was to elucidate the mechanisms of ibuprofen solubilization, densification and release from the conjugate crystanules as well as its dose distribution in order to provide fundamental knowledge on important physicochemical, thermodynamic and system-specific parameters which are key indices for the optimization of drug-polymer conjugate design for the delivery of poorly soluble drugs. The process of melt-in situ-granulation-crystallization reduced the solubility slightly compared with pure ibuprofen, however, the ibuprofen-Ddex conjugate crystanules exhibited increased ibuprofen solubility to a maximum of 2.

Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.

The recent Food and Drug Administration (FDA) guidance for industry on adaptive designs is perhaps one of the important undertakings by CDER/CBER Office of Biostatistics. Undoubtedly, adaptive designs may affect almost all phases of clinical development and impact nearly all aspects of clinical trial planning, execution and statistical inference. Thus, it is a significant accomplishment for the Office of Biostatistics to develop this well-thought-out and all-encompassing guidance document.

A method for testing a prespecified subgroup in clinical trials.

In clinical trials, investigators are often interested in the effect of a given study treatment on a subgroup of patients with certain clinical or biological attributes in addition to its effect on the overall study population. Such a subgroup analysis would become even more important to the study sponsor if an efficacy claim can be made for the subgroup when the test for the overall study population fails at a prespecified alpha level. In practice, such a claim is often dependent on prespecification of the subgroup and certain implicit or explicit requirements placed on the study results due to ethical or regulatory concerns.

Novel ion chromatography technique for the rapid identification and quantification of saturated and unsaturated low molecular weight organic acids formed during the Fenton oxidation of organic pollutants.

The Fenton oxidation process is one of the most widely used technologies in the oxidation of organic pollutants. The identification and quantification of end products of these oxidation processes is of prime importance due to environmental concerns of pollution and toxicity. In this work, we have developed a highly sensitive, cheap, easy and rapid method of determining low molecular weight mono and dicarboxylic acids using ion exclusion chromatography with inverse chemical suppression and conductivity detection.

A ratio test in active control non-inferiority trials with a time-to-event endpoint.

There are essentially two kinds of non-inferiority hypotheses in an active control trial: fixed margin and ratio hypotheses. In a fixed margin hypothesis, the margin is a prespecified constant and the hypothesis is defined in terms of a single parameter that represents the effect of the active treatment relative to the control. The statistical inference for a fixed margin hypothesis is straightforward.

Some issues with composite endpoints in clinical trials.

This article discusses some important issues that may arise in the current usage of composite endpoints as primary endpoints for demonstrating the efficacy of new drugs in clinical trials. The discussion focuses on time-to-event composite endpoints. Issues discussed include validity of a composite endpoint, the often lack of follow-up of patients beyond first event, the analysis of a composite endpoint, its sub-composite and individual component endpoints and their interpretation.

Hypotheses and type I error in active-control noninferiority trials.

A fundamental assumption in the design and analysis of an active-control noninferiority trial is that the active control is truly effective. If this assumption does not hold, i.e.

Evaluation of health-related quality-of-life measures in oncology drug product applications: issues and concerns.

Health-related quality-of-life outcomes as reported by patients are valuable data and ideally should be critical to evaluating clinical benefit. The unblinded or open-label designs commonly adapted in oncology trials have the potential to introduce selection bias, reporting bias, and analyses bias. In this paper, issues surrounding use of patient reported outcomes to evaluate oncology drug products, including definition of hypothesis, study design, analysis, and interpretation of patient reported outcome data, are reported.

Industry, government, and academic panel discussion on multiple comparisons in a "real" phase three clinical trial.

A Food and Drug Administration (FDA)/Industry/Academic Panel Discussion on multiplicity aspects of a real Phase III clinical trial was held at the Third International Conference on Multiple Comparisons, August 6, 2002, in Bethesda, Maryland. The goal was to develop some consensus among industry, government, and academic statisticians concerning requirements and methods for multiplicity management in typical clinical trials. The session was tape-recorded; this article mostly comes from an edited transcript.

Design and analysis of non-inferiority mortality trials in oncology.

The recent revision of the Declaration of Helsinki and the existence of many new therapies that affect survival or serious morbidity, and that therefore cannot be denied patients, have generated increased interest in active-control trials, particularly those intended to show equivalence or non-inferiority to the active-control. A non-inferiority hypothesis has historically been formulated in terms of a fixed margin. This margin was historically designed to exclude a 'clinically meaningful difference', but has become recognized that the margin must also be no larger than the assured effect of the control in the new study.